QURE Uniqure N.V.
$46.35 -3.44%
Healthcare · Pharmaceutical Preparations
Uniqure N.V. (QURE) is a healthcare company in the Pharmaceutical Preparations industry. Shares last traded at $46.35, 35.2% below their 52-week high. Over the past year the stock is up 213.6%. Net profit margin is -1236.2%, below the peer median of -0.1%. Revenue declined 40.6% year over year.
Market Cap
—
Shares Out
—
EPS (TTM)
$-6.06
P/E Ratio
—
P/S Ratio
—
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$71.49
52-Week Low
$7.52
Volume
162,174
Avg Vol (3m)
96,670.952
Performance
1W
+72.92%
1M
+87.73%
3M
+203.14%
6M
+111.84%
YTD
+97.70%
1Y
+213.60%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
79.30
SMA (50)
$24.13
SMA (200)
$27.58
Price vs SMA50
+92.07%
Price vs SMA200
+68.06%
ATR (14)
$3.51
Financials
Revenue
$16M
Net Income
$-199M
Gross Margin
—
Operating Margin
-1151.4%
Net Margin
-1236.2%
Return on Equity
-133.3%
Return on Assets
-25.6%
Current Ratio
10.40
Debt / Equity
0.33
Revenue Growth (YoY)
-40.6%
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $-0.85 | 2026-05-05 |
| FY 2025 | $-3.46 | 2026-03-02 |
| Q3 2025 | $-2.90 | 2025-11-10 |
| Q2 2025 | $-1.49 | 2025-07-29 |
| Q1 2026 | $-0.82 | 2026-05-05 |
| FY 2025 | $-4.92 | 2026-03-02 |
Pharmaceutical Preparations peers
QURE vs 14 industry peers (Pharmaceutical Preparations), by market cap.
1–14 of 14
| LLY | Lilly (Eli) | $1.04T | 50.16 | 15.88 | 31.7% | -1.17% |
| JNJ | Johnson & Johnson | $549.8B | 20.51 | 5.84 | 28.5% | -2.42% |
| ONC | Beone Medicines Ltd. | $390.6B | 1361.26 | 73.10 | 5.4% | +2.83% |
| ABBV | AbbVie | $382.5B | 90.51 | 6.25 | 6.9% | -2.16% |
| MRK | Merck | $281.6B | 15.43 | 4.33 | 28.1% | -1.30% |
| ABT | Abbott Laboratories | $154.3B | 23.65 | 3.48 | 14.7% | +0.09% |
| PFE | Pfizer | $143.7B | 18.50 | 2.30 | 12.4% | -2.89% |
| VRTX | Vertex Pharmaceuticals | $114.6B | 28.99 | 9.55 | 32.9% | -1.63% |
| BMY | Bristol Myers Squibb | $110.3B | 15.63 | 2.29 | 14.6% | -2.35% |
| REGN | Regeneron Pharmaceuticals | $63.4B | 14.08 | 4.42 | 31.4% | +0.38% |
| ALNY | Alnylam Pharmaceuticals | $36.9B | 117.57 | 9.93 | 8.4% | -1.66% |
| TEVA | Teva Pharmaceutical Industries Ltd | $36.6B | 25.98 | 2.12 | 8.2% | -3.33% |
| ZTS | Zoetis | $33.1B | 12.37 | 3.49 | 28.2% | +2.09% |
| RPRX | Royalty Pharma Plc | $23.1B | 30.02 | 9.73 | 32.4% | -1.30% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.